Elevated immunoreactivity against class i histone deacetylases in adenomyosis

Gynecologic and Obstetric Investigation

Volumn 74, Issue 1, 2012, Pages 50-55

  Liu, Xishi ^a   Nie, Jichan ^a   Guo, Sun Wei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Adenomyosis; Dysmenorrhea; Epigenetic; Histone deacetylase; Immunohistochemistry; Severity

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3;

ADENOMYOSIS; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DYSMENORRHEA; ECTOPIC TISSUE; ENDOMETRIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MENSTRUAL CYCLE; MENSTRUATION; MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOMYOSIS; ADULT; DYSMENORRHEA; FEMALE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84864633113     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000336409     Document Type: Article

References (31)

1. Bergeron C, Amant F, Ferenczy A: Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006; 20: 511-521.
2. Farquhar C, Brosens I: Medical and surgical management of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006; 20:603-616.
3. Fedele L, Bianchi S, Frontino G: Hormonal treatments for adenomyosis. Best Pract Res Clin Obstet Gynaecol 2008; 22: 333-339.
4. Guo SW: Epigenetics of endometriosis. Mol Hu m Reprod 2009; 15: 587-607.
5. Liu X, Guo SW: A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril 2008; 89: 246-250.
6. Wu Y, Strawn E, Basir Z, Halverson G, Guo SW: Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endome-triosis. Epigenetics 2006; 1:106-111.
7. Nie J, Liu X, Guo SW: Promoter hypermeth-ylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a de-methylation agent. Reprod Sci 2010; 17: 995-1005.
8. Liu XS, Yuan L, Guo SW: Vaproic acid as a therapy for adenomyosis: a comparative case series. Reprod Sci 2010; 17:904-912.
9. Lu Y, Nie J, Liu X, Zheng Y, Guo SW: Tricho-statin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice. Hum Reprod 2010;25:1014-1025.
10. Liu X, Guo SW: Valproic acid alleviates generalized hyperalgesia in mice with induced adenomyosis. J Obstet Gynaecol Res 2011; 37: 696-708.
11. Mao X, Wang Y, Carter AV, Zhen X, Guo SW: The retardation of myometrial infiltration, reduction of uterine contractility, and alleviation of generalized hyperalgesia in mice with induced adenomyosis by levo-tetrahy-dropalmatine (l-THP) and andrographolide. Reprod Sci 2011; 18: 1025-1037.
12. Cedar H, Bergman Y: Linking DNA meth-ylation and histone modification: patterns a nd paradigms. Nat Rev Genet 2009; 10: 295-304.
13. Kim HJ, Bae SC: Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011; 3: 166-179.
14. Glozak MA, Sengupta N, Zhang X, Seto E: Acetylation and deacetylation of non-his-tone proteins. Gene 2005; 363:15-23.
15. Liu XF, Bagchi MK: Recruitment of distinct chromatin-modifying complexes by tamox-ifen-complexed estrogen receptor at natural target gene promoters in vivo. J Biol Chem 2004; 279: 15050-15058.
16. Uchida H, Maruyama T, Nagashima T, Ono M, Masuda H, Arase T, Sugiura I, Onouchi M, Kajitani T, Asada H, Yoshimura Y: Human endometrial cytodifferentiation by his-tone deacetylase inhibitors. Hum Cell 2006; 19: 38-42.
17. Uchida H, Maruyama T, Ohta K, Ono M, Arase T, Kagami M, Oda H, Kajitani T, Asa-da H, Yoshimura Y: Histone deacetylase inhibitor-induced glycodelin enhances the initial step of implantation. Hum Reprod 2007; 22: 2615-2622.
18. Uchida H, Maruyama T, Ono M, Ohta K, Kajitani T, Masuda H, Nagashima T, Arase T, Asada H, Yoshimura Y: Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 2007; 148:896-902.
19. Krusche CA, Vloet AJ, Classen-Linke I, von Rango U, Beier HM, Alfer J: Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarci-nomas. Hum Reprod 2007; 22: 2956-2966.
20. Weichert W, Denkert C, Noske A, Darb-Es-fahani S, Dietel M, Kalloger SE, Huntsman DG, Kobel M: Expression of class I histone deacetylases indicates poor prognosis in en-dometrioid subtypes of ovarian and endo-metrial carcinomas. Neoplasia 2008; 10: 1021-1027.
21. Nie J, Liu X, Guo SW: Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its correlation with dysmenorrhea in adenomyosis. Am J Obstet Gynecol 2010; 202:346.e341-e348.
22. Liu X, Nie J, Guo SW: Elevated immunoreac-tivity to tissue factor and its association with dysmenorrhea severity and the amount of menses in adenomyosis. Hum Reprod 2011; 26: 337-345.
23. Diaz A, Laufer MR, Breech LL: Menstruation in girls and adolescents: Using the menstrual cycle as a vital sign. Pediatrics 2006; 118: 2245-2250.
24. Nie J, Lu Y, Liu X, Guo SW: Immunoreactiv-ity of progesterone receptor isoform b, nuclear factor kappab, and ikappabalpha in ade-nomyosis. Fertil Steril 2009; 92:886-889.
25. Shen F, Wang Y, Lu Y, Yuan L, Liu X, Guo SW: Immunoreactivity of progesterone receptor isoform b and nuclear factor kappa-b as biomarkers for recurrence of ovarian en-dometriomas. Am J Obstet Gynecol 2008; 199: 486 e481-486 e410.
26. Wang-Tilz Y, Tilz C, Wang B, Tilz GP, Stefan H: Influence of lamotrigine and topiramate on mdr1 expression in difficult-totreat temporal lobe epilepsy. Epilepsia 2006; 47: 233-239.
27. Team' RDC: R: A language and environment for statistical computing. Vienna, Austria, R Foundation for Statistical Computing, 2011.
28. Guo SW: The endometrial epigenome and its response to steroid hormones. Mol Cel En-docrin 2011; In press.
29. Xishi L, Lei Y, Guo SW: Valproic acid as a therapy for adenomyosis: A comparative case series. Reprod Sci;17: 904-912.
30. Kondo Y: Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J 2009; 50: 455-463.
31. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A: Tran-scriptional repression by the methyl-cpg-binding protein mecp2 involves a histone deacetylase complex. Nature 1998; 393: 386-389.